Fidarestat is primarily used in the treatment of diabetic complications, particularly diabetic neuropathy. It works by inhibiting aldose reductase, an enzyme that plays a key role in the polyol pathway. By blocking this enzyme, Fidarestat helps reduce the accumulation of sorbitol in nerve cells, which is a major contributor to nerve damage in diabetic patients. This action helps alleviate symptoms such as pain, numbness, and tingling in the extremities. Additionally, Fidarestat has shown potential in preventing or slowing the progression of other diabetes-related complications, such as retinopathy and nephropathy, by mitigating oxidative stress and improving cellular function. Its application is particularly significant in managing chronic diabetic conditions and improving the quality of life for patients.